Insulin resistance and lipid profiles in HIVinfected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy

Journal of Pediatric Endocrinology and Metabolism

Volumn 27, Issue 5-6, 2014, Pages 403-412

  Dejkhamron, Prapai ^a   Unachak, Kevalee ^a   Aurpibul, Linda ^b   Sirisanthana, Virat ^b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Adipokines; Human immunodeficiency virus 1; Insulin resistance; Lipid profiles; Lopinavir ritonavir

Indexed keywords

ADIPONECTIN; ANTIRETROVIRUS AGENT; GLUCOSE; INSULIN; LEPTIN; LOPINAVIR PLUS RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA; ADIPOCYTOKINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLUCOSE BLOOD LEVEL; LIPID; LOPINAVIR; RITONAVIR;

ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; EARLY DIAGNOSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST; THAILAND; VIRUS LOAD; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; DYSLIPIDEMIAS; GLUCOSE BLOOD LEVEL; HIV INFECTIONS; METABOLISM; PHYSIOLOGY; PREGNANCY; PRESCHOOL CHILD;

ADIPOKINES; ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIPIDS; LOPINAVIR; MALE; PREGNANCY; RITONAVIR; THAILAND;

EID: 84902474852     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2013-0253     Document Type: Article

References (39)

1. Eyzaguirre F, Mericq V. Insulin resistance markers in children. Horm Res 2009;71: 65-74.
2. Feeney ER, Mallon PW. Insulin resistance in treated HIV infection. Best Pract Res Clin Endocrinol Metab 2011;25: 443-58.
3. Taylor SA, Lee GA, Pao VY, Anthonypillai J, Aweeka FT, et al. Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. J Acquir Immune Defic Syndr 2010;55: 361-4.
4. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, et al. Single-dose lopinavir-ritonavir acutely nhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis. 2006;43: 658-60.
5. Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004;18: 2137-44.
6. Hruz PW. Molecular mechanisms for insulin resistance in treated HIV-infection. Best Pract Res Clin Endocrinol Metab 2011;25: 459-68.
7. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23: 35-43.
8. Carr A, Samaras K, Burton S, Law M, Freund J, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
9. Stanley TL, Grinspoon SK. Body composition and metabolic changes in HIV-infected patients. J Infect Dis 2012;205 Suppl 3:S383-90.
10. Dube MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab 2011;25: 429-42.
11. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS. 2004;18: 641-9.
12. Calza L, Manfredi R, Farneti B, Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents 2003;22: 54-9.
13. Strehlau R, Coovadia A, Abrams EJ, Martens L, Arpadi S, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr 2012;60: 369-76.
14. Rhoads MP, Lanigan J, Smith CJ, Lyall EG. Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. J Acquir Immune Defic Syndr 2011;57: 404-12.
15. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviralnaive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010;53: 323-32.
16. Kosalaraksa P, Bunupuradah T, Engchanil C, Boonrak P, Intasan J, et al. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks. Pediatr Infect Dis J 2008;27: 623-8.
17. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005;24: 874-9.
18. Vigano A, Zuccotti GV, Cerini C, Stucchi S, Puzzovio M, et al. Lipodystrophy, insulin resistance, and adiponectin concentration in HIV-infected children and adolescents. Curr HIV Res. 2011;9: 321-6.
19. Resino S, Palladino C, Lorente R, Micheloud D, Bellon JM, et al. Association between lipodystrophy and leptin in human immunodeficiency virus-1-infected children receiving lopinavir/ritonavir-based therapy. Pediatr Infect Dis J. 2010;29: 774-7.
20. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children < 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. Morb Mortal Wkly Rep 1994;43: 1-10.
21. Aurpibul L, Puthanakit T, Lee B, Mangklabruks A, Sirisanthana T, et al. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitorbased antiretroviral therapy. Antivir Ther 2007;12: 1247-54.
22. Reaven GM, Chen YD, Hollenbeck CB, Sheu WH, Ostrega D, et al. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 1993;76: 44-8.
23. Valerio G, Licenziati MR, Iannuzzi A, Franzese A, Siani P, et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. Nutr Metab Cardiovasc Dis 2006;16: 279-84.
24. Yeckel CW, Taksali SE, Dziura J, Weiss R, Burgert TS, et al. The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance. J Clin Endocrinol Metab 2005;90: 747-54.
25. Inzucchi SE. Clinical practice. Diagnosis of diabetes. N Engl J Med 2012;367: 542-50.
26. Kwiterovich PO Jr. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab 2008;93: 4200-9.
27. Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab 2004;89: 2526-39.
28. Levy-Marchal C, Arslanian S, Cutfield W, Sinaiko A, Druet C, et al. Insulin resistance in children: consensus, perspective, and future directions. J Clin Endocrinol Metab 2010;95: 5189-98.
29. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500-3.
30. Yeckel CW, Weiss R, Dziura J, Taksali SE, Dufour S, et al. Validation of insulin sensitivity indices from oral glucose tolerance test parameters in obese children and adolescents. J Clin Endocrinol Metab 2004;89: 1096-101.
31. dos Reis LC, de Carvalho Rondo PH, de Sousa Marques HH, de Andrade SB. Dyslipidaemia and insulin resistance in vertically HIV-infected children and adolescents. Trans R Soc Trop Med Hyg 2011;105: 197-203.
32. Rosso R, Parodi A, d'Annunzio G, Ginocchio F, Nicolini L, et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol 2007;157: 655-9.
33. Geffner ME, Patel K, Miller TL, Hazra R, Silio M, et al. Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. Horm Res Paediatr 2011;76: 386-91.
34. Esmailzadeh N, Wongsabut J, Petwijit T, Kosalaraksa P, Suntarattiwong P, et al. Prevalence of insulin resistance and metabolic syndrome among HIV-infected children receiving lopinavir/ritonavir-based antiretroviral therapy [Abstract no. MOPDB0102]. In: 7TH IAS Conference on HIV Pathogenesis, Treatment and Prevention. Jun 30 to Jul 03, 2013. Kuala Lumpur, Malaysia.
35. Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther 2009;14: 241-8.
36. Ramos JT, De Jose MI, Duenas J, Fortuny C, Gonzalez-Montero R, et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J 2005;24: 867-73.
37. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365: 1415-28.
38. Luo L, Zhang L, Tao M, Qiu Z, Xie J, et al. Adiponectin and leptin levels in Chinese patients with HIV-related lipodystrophy: A 30-month prospective study. AIDS Res Hum Retroviruses 2009;25: 1265-72.
39. Dzwonek AB, Novelli V, Schwenk A. Serum leptin concentrations and fat redistribution in HIV-1-infected children on highly active antiretroviral therapy. HIV Med 2007;8: 433-8.